Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 3/20 | 0.33 |
| ▸ | CTSH | P09668 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27591335 | 0.77 | CTSK (0.37) | CTSKCTSLCTSBCTSHKMT2A | |
| SCHEMBL756416 | 0.75 | GRN (0.36) | CTSKCTSLCTSBCTSHKMT2A | |
| SCHEMBL4716380 | 0.75 | MEN1 (0.41) | CTSKCTSLCTSBCTSHKMT2A | |
| SCHEMBL4716376 | 0.75 | KMT2A (0.35) | CTSKKMT2AMEN1EPHX1HPGD | |
| SCHEMBL16203420 | 0.75 | MEN1 (0.41) | CTSKCTSLCTSBCTSHKMT2A | |
| SCHEMBL23970178 | 0.75 | MEN1 (0.41) | CTSKCTSLCTSBCTSHKMT2A | |
| SCHEMBL6826573 | 0.74 | ADH1B (0.42) | CTSKCTSLCTSBKMT2AMEN1 | |
| SCHEMBL5850026 | 0.74 | CYP2D6 (0.40) | CTSKCTSLCTSB | |
| SCHEMBL3599961 | 0.74 | CYP2D6 (0.40) | CTSKCTSLCTSB | |
| SCHEMBL3599965 | 0.74 | CYP2D6 (0.40) | CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | CTSK 728/4885CTSL 907/4885CTSB 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.